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Abstract: This work is a continuation of our research into the development of simple, reliable, and
cost-effective methods for the early diagnosis of prostate cancer (PCa). The proposed method is based
on the electrochemical detection of the PCA3 biomarker of PCa (long non-coded RNA transcript
expressed in urine) using a specific aptamer labeled with a redox group (methylene blue). The
electrochemical measurements (cyclic voltammograms) obtained from electrodes functionalized
with the aptamer were complemented in this work by another biosensing technique: total internal
reflection ellipsometry (TIRE). In addition to proving the concept of the detection of PCA3 in low
concentrations down to 90 pM, this study improved our understanding of the processes by which
PCA3 binds to its specific aptamer. The high specificity of the binding of PCA3 to the aptamer was
assessed by studying the binding kinetics, which yielded an affinity constant (KD) of 2.58 × 10
−9 M.
Additional XPS measurements confirmed the strong covalent binding of aptamers to gold and
showed spectral features associated with PCA3 to aptamer binding.
Keywords: prostate cancer; PCA3; aptamers; cyclic voltammograms; spectroscopic ellipsometry; XPS
1. Introduction
Improving the diagnostic tools used for the early diagnosis of prostate cancer (PCa),
one of the most common cancers in men, is of high importance today [1]. The currently
used method, which is based on the detection of prostate specific antigen (PSA) in blood
serum, is not entirely reliable because of the possibility of both false-positive and false-
negative results [2]. Several other biomarkers for prostate cancer are known [3], including
PCA3, a long non-coded RNA transcript expressed in the urine of prostate cancer patients,
which appears to be an ideal biomarker of PCa [4]. Although PCA3 was discovered a
long time ago, until now, its use in prostate cancer diagnosis has been limited to the
Progensa PCA assay, licensed in the USA in 2012. This assay detects PCa through PCR
amplification of the mRNA of both PCA3 and PSA in the first-catch urine after a digital
rectal examination and yields a PCA3 score (the ratio of PCA3 to PSA mRNA molecules in
urine specimens) [5,6]. Studies regarding the clinical utility of the PCA3 urine assay for
men in Europe and North America confirmed that a PCA3 score cut-off of 35 provides an
optimal balance between sensitivity and specificity for PCa detection [6,7]. The diagnostic
accuracy is not affected by age, the number of previous negative biopsies, total PSA ranges,
or prostate volume [6,7]. Furthermore, this study showed that men with clinical stage T2 or
“significant” PCa (biopsy Gleason score ≥ 7) had a substantially higher PCA3 score than
men with clinical stage T1 or “indolent” PCa (biopsy Gleason score < 7) [7]. Therefore, the
clinical stage and severity of PCa may be related to the PCA3 score. The PCA3 score has
recently been connected to tumor volume and Gleason scores in prostatectomy samples [8]
and demonstrated its potential in minimizing the number of unnecessary biopsies, as well
as the cost of treatment [9].
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Despite several advantages, the Progensa test is quite expensive and time-
consuming [10,11]. Several attempts have been made recently to develop novel ap-
proaches for the detection of PCA3 [12–16], including the use of aptamers as specific
bioreceptors for PCA3 [16–18]. The use of aptamers is particularly attractive because of
their superior stability, simplicity, and low-cost of synthesis which allows for the function-
alization of aptamers with various functional groups (i.e., thiols, redox, and fluorescent
labels), and introduces the possibility of aptamer recovery in comparison to traditional
antibodies [19,20]. The application of aptamers in medical diagnostic tools as biorecep-
tors for biomarkers of different types of cancers has risen dramatically in the last few
years [21–25]. The detection of PCA3 in aptamer assays was reported recently in several
publications [17,18,26].
Simple electrochemical methods for the detection of PCA3 using specific aptamers
labeled with a redox group (ferrocene) were demonstrated in our previous publication [26].
While the detection principle has been proven, there are still many questions that remain
unanswered. For instance, the changes in aptamer configuration when binding to the PCA3
target need further investigation and the concentration of aptamers immobilized on the
surface must be optimized to achieve a wider dynamic range of detection. The choice of the
aptamer type (DNA or RNA) and the use of different redox labels related to the aptamer
type also need to be considered. In this work, we tried to address the above problems
using different types of aptamers (RNA-based), including aptamers that are non-labeled
and labeled with methylene blue, as well as different experimental methods. In addition
to the previously used electrochemical method of cyclic voltammograms, we explored
spectroscopic ellipsometry of total internal reflection (TIRE). The processes of aptamer
immobilization on the surface of gold and PCA3 to aptamer binding were studied using
X-ray photoelectron spectroscopy (XPS).
2. Results and Discussion
2.1. Electrochemical Detection of PCA3 Using Aptamer Labeled with Methylene Blue
The typical series of cyclic voltammograms (CVs) of gold screen-printed electrodes
(SPE) with an immobilized aptamer specific to PCA3 are shown in Figure 1a. The CV of
the aptamer layer showed no specific features in the middle of the scan range (−0.3 V
to 0.2 V). Binding the target analyte (PCA3) to the aptamer caused the appearance of
oxidation and reduction peaks at about −0.05 V and −0.06 to −0.08 V, respectively, which
are associated with the oxidation and reduction potentials of methylene blue [27]. The peak
intensity increased with an increase in the concentration PCA3. The smallest concentration
of PCA3 used was 1 nM, and it yielded barely noticeable peaks. It should be noted that
the peak current values increase with an increase in the scan rate, which is expected
for systems without redox chemicals in the solution (see Figure S1 in Supplementary
Materials). A scan rate of 40 mV/s was chosen as optimal in terms of the signal amplitude
and stability. Negative control experiments were carried out using the non-complementary
PCA3 molecule with a scrambled sequence of nucleotides. The resulting CV (green curve)
has no characteristic features similar to that of freshly deposited aptamers.
Differential pulse voltammetry (DPV) yielded better results (see Figure 1b) with
well-resolved reduction peaks at −0.16 V. DPV is the preferable technique for sensing
applications. Evaluating the low detection limit was not the goal in this research study, since
we aimed to prove the concept of detection; however, the minimum detected concentration
of 1 nM is sufficient for PCa diagnosis based on the PCA3 biomarker.
The mechanism of detection can be understood from the diagram in Figure 2. In the
freshly deposited stretched aptamers in Figure 2a, the methylene blue labels (shown as
blue circles) are far away from the gold surface, so that the charge transfer is negligibly
small and, therefore, the current peaks do not appear on the CV. The binding process of
PCA3 to the aptamer involves the aptamer engulfing the target, thus bringing the redox
labels closer to the gold surface and subsequently increasing the charge transfer (CT) and
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the amplitude of both oxidation and reduction peaks, as illustrated in Figure 2b. Biomark-
ers non-complementary to the aptamer molecules (PCA3 with a scrambled nucleotide
sequence) would not bind to the aptamer and would not cause the above characteristic
features in both CV and DPV. Additionally, the non-specific binding of PCA3, which can
occur at high concentrations of PCA3 when all the binding sites are occupied and PCA3
molecules pile up on top of the first layer, would not cause an increase in the current since
the additional redox labels are away from the surface. It is important to note that the
success of DPV and the dependence of redox peaks on the scan rate can be attributed to
























Figure 1. (a) A series of CV curves for a 1 µM aptamer layer immobilized on the surface of the SPE
before and after binding PCA3 of different concentrations, including a negative control; (b) DPV





















Figure 2. Schematic diagram of redox-labeled aptamers (blue circle) immobilized on the surface of
gold before (a) and after binding the PCA3 target (green shape), which causes an increase in the
charge transfer (CT) (b).
The charge transfer can be improved by adding redox-active chemicals to the elec-
trolyte; however, this may lead to a completely different concept of detection in which
the aptamer layer blocks the charge transfer. Another interesting point to discuss is the
concentration of aptamers immobilized on the surface. It seems that increasing the concen-
tration of the aptamers can increase the concentration of binding sites and thus enhance
the sensitivity of detection. On the other hand, a high surface concentration of aptamers
may not provide sufficient space for aptamer coiling, thus limiting the sensor response.
Therefore, the concentration of aptamers should be optimized.
2.2. Optical Detection of PCA3 with Non-Labeled Aptamer Using the Method of Total Internal
Reflection Ellipsometry (TIRE)
Optical detection of PCA3 with the use of the TIRE method, which does not require the
use of labeled aptamers, could provide additional information on the processes associated
with PCA3 to aptamer binding. The TIRE method described in detail in Section 3.4
was deployed here for the detection of PCA3 in direct assay with its specific non-labeled
aptamers immobilized on the surface of Cr-Au-coated glass slides. The TIRE measurements
were performed in standard phosphate buffer solution (PBS; pH 7) on a layer of aptamers
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before and after binding PCA3 of sequentially increasing concentrations: 0.09, 0.5, 10,
and 100 nM. PCA3 solutions of different concentrations (starting from the smallest) were
injected into the cell using a syringe and kept there for sufficient time to complete binding.
Then, the cell was rinsed with PBS by purging 10× the cell volume. Following that, the
steady TIRE spectra were recorded.
The typical series of the TIRE ∆ spectra for the aptamer layer of 4 µM are shown
in Figure 3a. The ∆ spectra appear to be blue shifted up to a PCA3 concentration of
10 nM, which corresponds to a decrease in the aptamer layer thickness. Then, at the
high concentration of PCA3 (100 nM), a red spectral shift occurs, corresponding to an
increase in the thickness. The values of thickness of the aptamer layer were found by fitting
the TIRE spectra to a four-layer model BK7 glass (prism)/Cr-Au metal layer/aptamer
layer/aqueous medium (buffer). The data fitting procedure is explained in detail in our
previous publications, for example, [28]. The optical constants of materials: BK7 glass,
buffer solution, Cr and Au, were used from the J.A. Woollam library available within
VWASE or CompleteEASE software, while the refractive index (n) of the aptamer layer
is described by the Cauchy model: n = An + Bn/λ2 + Cn/λ4, with fixed parameters:
An = 1.4, Bn = 0.01, and Cn = 0, which gives n = 1.42, typical for the majority of proteins
and polynucleotides including aptamers. The extinction coefficient k = 0 was used since
the aptamer layer was optically transparent in the spectral range used [28].
 
Ψ
Figure 3. (a) A series of TIRE ∆ spectra recorded on a 4 µM aptamer layer immobilized on Au (1) and
after binding PCA3 in different concentrations: 0.09 (2), 0.5 (3), 10 (4), and 100 nM (5). (b) Changes in
the thickness of the aptamer layers caused by the binding of PCA3 at different concentrations.
The obtained values of aptamer layer thickness shown in Figure 3b demonstrate the
initial decrease in the film thickness at low concentrations of PCA3, followed by an increase
in thickness at high concentrations of PCA3. This trend is even more pronounced for low
concentrations of aptamers (1 µM). Such behavior can be explained using the model of
PCA3 to aptamer binding given in Figure 4. The initial thickness of a layer of freshly
immobilized stretched aptamers is typically in the range of 7 to 8 nm (Figure 4a). After
binding to PCA3, the thickness of the aptamer layer decreases (as shown in Figure 5b)
because the aptamers wrap around the PCA3 target. When all the binding sites (aptamers)
are occupied, the binding reaches saturation that can be observed in Figure 4b. The smaller
the concentration of the immobilized aptamer, the earlier that saturation occurs. After that,
if the concentration of PCA3 increases further, non-specific binding takes place as PCA3
molecules pile on top of the complete layer (see Figure 4c), which increases the aptamer
layer thickness, as shown in Figure 4b.
The kinetics of PCA3 to aptamer binding was studied using dynamic TIRE measure-
ments (mentioned in Section 3.4). The typical TIRE kinetics for Ψ fixed at 700 nm was
recorded during the binding of PCA3 at different concentrations to aptamers. The typical
results are given in Figure 5a. The curves were fitted using exponential decay functions and
the obtained values of the time constant (τ) are presented in the graph. The results show
that the τ values decrease with an increase in PCA3 concentration. Regarding the TIRE
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measurements, the selection of the PCA3 incubation time depends on its concentration; the
duration of 3τ is sufficient to achieve the saturation of binding.
A noticeable finding is that at the highest concentration of PCA3 (100 nM), the ex-
ponential decay in Ψ takes place only in the first 5 min, and it is followed by its increase,
which is attributed to the non-specific adsorption of PCA3.
Ψ
Figure 4. Schematic of a layer (with the thickness d) of non-labeled aptamers immobilized on
the surface of gold before (a) and after binding the PCA3 target (green shapes) accompanied by








‒ ‒ ‒ ‒
‒
Figure 5. (a) Time dependencies of Ψ at 700 nm during the binding of PCA3 at different concentrations to the 4 µM aptamer;
(b) evaluation of the affinity constant from 1/τ vs. C dependance.
According to the theory of molecular binding to a monolayer of binding sites on the
surface (a model suitable for our case of aptamers immobilized on the surface of gold) [29],
the reciprocal of the time constant (1/τ) is linearly dependent on the analyte (PCA3)
concentration (C): 1/τ = kaC + kd, where ka and kd are the adsorption and desorption
rates, respectively. The affinity constant KD can be found as KD = kd/ka. The results in
Figure 5a were processed as described above, and the linear dependence of 1/τ vs. PCA3
concentration in Figure 5b yielded the value of the affinity constant: KD = 2.58 × 10
−9 M.
The value obtained is similar to that reported by the founders of the CG-3 RNA aptamer [30],
confirming once again the extremely high specificity of this aptamer toward PCA3.
2.3. XPX Study
X-ray photoelectron spectroscopy (XPS) is a common analytical tool for elemental
surface analysis, and it has recently been used in the characterization of aptamers immo-
bilized on different surfaces [22–24,29]. The samples used for XPS measurements were
prepared by immobilizing aptamers (from their 1 µM and 4 µM solutions) on Cr-Au-coated
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glass slides followed by drop-casting PCA3 solutions of two different concentrations (low,









Figure 6. Typical XPS spectral peaks for: S 1 s in aptamer (a), O 1 s in aptamer (b) and after binding PCA3 (c), C 1 s in
aptamer (d) and after binding PCA3 (e), N 1 s (f) in aptamer, and P 2p in aptamer after binding PCA3 (g).
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To confirm the successful immobilization of aptamers on the surface of Au, the peaks
of S 2p were analyzed. All samples containing immobilized aptamers showed two char-
acteristic peaks at about 162 and 163.3 eV (Figure 6a), which correspond to the S of the
aptamers’ thiol groups bound to Au [29], while there were no such peaks on the bare
Au surface. The characteristic XPS peaks associated with O 1s are shown in Figure 6b,c.
It should be noted that in addition to a single O 1s peak at about 532.5 eV (Figure 6b),
associated with C–O bonding [29] in the aptamer layer, a second peak appeared at about
532.5 eV after binding PCA3 (Figure 6c). The latter peak associated with H–C–O bond-
ing [31] indicates the formation of a hydrogen bond between the aptamer and PCA3. XPS
spectra for C 1s in Figure 6d and e show three peaks at about 285, 286.5, and 288.5 eV
corresponding to the C–C, C–O, and O–C=O bonds, respectively [31]. The increase in the
C–O and O–C=O peaks in Figure 6e can be attributed to the formation of hydrogen bonds
between the aptamer and PCA3 upon bending. The XPS peak related to N 1s at about
400.3 eV in Figure 6f, which appeared only on samples with aptamers, is quite small, and
its intensity slightly increases after binding PCA3. Finally, the XPS peaks of P 2p at about
134.1 and 133.5 eV in Figure 6g are quite small and appeared on samples with aptamers
after binding PCA3. Changes in the concentration of both immobilized aptamers and
aptamers bound to PCA3 did not have significant effects on the XPS spectra and, in some
samples, the peak intensities were smaller for lower concentrations. All the results shown
in Figure 6b–g confirmed the formation of the aptamer-PCA3 complex on the surface.
3. Materials and Methods
3.1. Aptamers and Target Analyte
The HPLC-purified CG-3 RNA-based aptamer, 5′-MHB-AGUUUUUGCGUGUGCCCUU
UUUGUCCCC-SH-3′ specific to 277 bases of PCA3 transcript, was purchased from Merck
Life Science UK Limited, (Dorset, England). This CG-3 RNA-based aptamer sequence
generated against the 277 nt section of the PCA3 transcript by SELEX technology was first
reported by Marangoni et al. [30]. The aptamers were functionalized with a thiol (SH)
group at C3′ termini for further immobilization on the surface of gold. The redox functional
groups of methylene blue attached at the C5′ termini were used as electron mediators to
provide distinctive electrochemical properties. A batch of aptamers without redox labels
was also produced. Aptamers delivered in the lyophilized form were then dissolved in
Tris buffer (10 mM TRIS-HCL, 0.5 mM disodium EDTA, pH 7.8) and stored at −20 ◦C in
small aliquots to avoid repeating thaw-freeze cycles.
The target analyte, a 78 bp fragment of lncRNA-PCA3 having a molecular mass
of 25,048.3 g/mol, was purchased from Eurofins Scientific (Manchester, UK) and pre-
pared in PBS (pH 7.5). All other chemicals used were purchased from Sigma-Aldrich
(Haverhill UK) which included the HEPES and phosphate binding buffers (HBB and
PBB) and 1,4-dithiothreitol (DTT). All aqueous solutions were prepared using 18.2 MX cm
ultra-pure water (Millipore Ltd., Livingston, UK) with a pyro Gard filter (Millipore) to
remove nucleases.
3.2. Immobilization of Aptamers, Electrochemical and Optical Sensor Fabrication
The aptamer stock solution was diluted to desired concentrations of 1 and 4 µM
in the immobilization buffer, which consisted of HEPES binding buffer (HBB) (pH 7.4),
supplemented with 1 mM of 1,4-dithiothreitol (DTT), and 3 mM of MgCl2. The addition
of MgCl2 was essential to preserve the aptamer single RNA strand from self-coiling.
Unreacted aptamers were removed from the electrode surface by several rinses with a
non-folding buffer. Before immobilization, the aptamer liquid samples were activated by
rapid heating to 95 ◦C for 5 min, followed by 5 min of cooling at 4 ◦C in a thermocycler
(Prime TC3600) to achieve the correctly unfolded structure.
For electrochemical measurements, the redox-labeled aptamers were immobilized
on the surface of gold screen-printed three-electrode assemblies (DropSens, Metrohm UK
Ltd., Runcorn, UK) cleaned by sonication in acetone for 3 min and dried with nitrogen gas
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flow. Immobilization of aptamers was carried out by casting an aptamer solution (about
40 µL onto the surface of the screen-printed gold electrodes) and the samples were then
incubated for 5 h at room temperature in a humidity chamber. The same immobilization
protocol was used for the non-labeled aptamers during sample preparation for optical
spectroscopic ellipsometry measurements. The samples were based on BK7 microscopic
glass slides cleaned in Piranha solution, rinsed with de-ionized water, and dried under
nitrogen gas flow. The layers of Cr (3–5 nm) and Au (20–25 nm) were deposited on clean
glass slides using thermal evaporation in an Edwards 360 evaporation unit under a vacuum
of 10−6 Torr. A thin layer of Cr was used to improve the adhesion of the Au layer to the
glass. Both the screen-printed gold electrodes and the Cr-Au-coated glass slides with
immobilized aptamers were kept at 4 ◦C in HBB to prevent the aptamers from coiling.
The lncRNA-PCA3 target analytes were re-suspended in electrolyte buffer (HEPES pH
7.5, 120 mm NaCl, and 5 mm KCl) at different concentrations from 100 nM down to 0.09 nM
and were used in electrochemical measurements. PCA3 solutions in HEPES buffer (pH 7.5)
of similar concentrations were used in optical spectroscopic ellipsometry measurements.
3.3. Cyclic Voltammogram Measurements
Cyclic voltammogram (CV) measurements were carried out on three-electrode DropSens
gold screen-printed assemblies with Ag/AgCl as the reference electrode using potentiostat
STAT8000P from DropSens (Metrohm UK Ltd., Runcorn, UK). A voltage range from −0.3
to 0.2 V was used in CV measurements with an optimized scan rate (40 mV/S) recorded
5 times until the current readings were stabilized. In addition to cyclic voltammetry,
the differential pulse voltammetry (DPV) of PCA3 under different concentrations was
recorded using a pulse amplitude of 20 mV and a scan rate of 10 mV/s. Both CV and
DPV measurements were carried out on electrodes with immobilized aptamers immersed
in an electrolyte buffer containing different concentrations of PCA3 from 1 ng/mL to
1000 ng/mL; measurements of buffer alone were used as a reference. Negative control
measurements were carried out using non-complementary fragments of lncRNA-PCA3
with a scrambled nt sequence.
3.4. Spectroscopic Ellipsometry Measurements
The method of total internal reflection ellipsometry (TIRE) was used in this work as
an alternative experimental technique for the quantification of PCA3 to aptamer binding.
TIRE, also known as phase SPR (surface plasmon resonance), was experimentally realized
by Poksinsky and Arvin [32] in 2005 as a combination of spectroscopic ellipsometry instru-
mentation and SPR total internal reflection geometry. This method was quickly adapted by
our research group and successfully applied for different biosensing applications [33–37].
The experimental set-up shown in Figure 7a is based on the spectroscopic ellipsometer
M2000 (J. A. Woollam Co., Lincoln, NE, USA) with the addition of a 68◦ glass prism, which
provides total internal conditions for light coupling into glass slides coated with a thin
Cr-Au layer. A PTFE cell of 0.2 mL in volume was sealed to the gold side of a slide. The
whole assembly of the prism/gold-coated slide/cell was placed on the ellipsometer stage.
In contrast to traditional SPR equipment recording the intensity of reflected light, in the
TIRE method, the spectra of two parameters Ψ and ∆ are recorded, where Ψ is the ratio of
amplitudes of the p- (in the plane of incidence) and s- (normal to the plane of incidence)
components of the electric field vector of polarized light (tan(Ψ) = Ep/Es), and ∆ is the
phase shift between Ep and Ep (∆ = φp − φs).
The typical TIRE spectra of Ψ and ∆ are shown for Cr-Au-coated slides with the layer
of bioreceptors (aptamers) in contact with the aqueous medium (buffer) in Figure 7b. The
spectrum exhibits an SPR-like shape for Ψ, with the minimum corresponding to plasmon
resonance, while the ∆ spectrum shows a sharp drop near the resonance position at which
it appears to be extremely sensitive to changes in the thickness or refractive index of the
molecular layer [35]; that is why the TIRE method is particularly beneficial for the detection
of small molecules such as mycotoxins [33–37]. Typically, an increase in the layer thickness
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corresponds to a red TIRE spectral shift. The TIRE method also allowed for studying the
kinetics of molecular adsorption (or binding) by recording the Ψ and ∆ spectra many times
after a certain time interval during the process of molecular adsorption and then plotting
the values of Ψ or ∆ at a particular wavelength vs. time. Both steady-state and dynamic
TIRE measurements were carried out in this work.
−




Figure 7. (a) TIRE experimental set-up based on the spectroscopic ellipsometer instrument with a light source (LC), polarizer
(P), compensator (C), analyzer (A), and a CCD photodetector with the SPR unit attachment consisting of a glass prism
(1), a Au-coated glass slide (2), and a PTFE cell (3) placed on the ellipsometer stage; (b) typical TIRE spectra of Ψ and ∆
recorded on a Cr-Au-coated glass slide with a layer of aptamers immobilized on the Au surface.
3.5. X-ray Photoelectron Spectroscopy (XPS) Measurements
XPS measurements were performed using a Kratos Supra X-ray photoelectron spec-
trometer (Kratos Analytical, Manchester, UK) with a monochromatic Al Kα X-ray source
(1486 eV). The area of analysis was 300 × 700 µm. The survey spectra were acquired at pass
energy of 160 eV. High-resolution scans for C 1s, N 1s, O 1s, Au 4f, S 2p, and P 2p spectral
bands were collected over appropriate energy ranges. All XPS spectra were analyzed and
curve-fitted using the Casa XPS software; all spectra were calibrated relative to the C 1 s
signal at a binding energy of 285.0 eV. Measurements were repeated twice, and the errors
quoted in the numerical data represent the standard deviations.
4. Conclusions
The study of binding a fragment of the 277 nt lncRNA transcript of PCA3 to a specific
CG-3 RNA aptamer was carried out using several experimental methods: cyclic voltam-
mograms, total internal reflection ellipsometry, and X-ray photoelectron spectroscopy. CV
and DPV measurements proved the concept of electrochemical detection of the prostate
cancer marker PCA3 using aptamers labeled with methylene blue. This method appeared
not to be affected by non-specific adsorption of PCA3 at high concentrations. This work
was not focused on the evaluation of the sensitivity of both the electrochemical and optical
detection, but rather on the qualitative comparison of the two methods. The smallest
concentration of PCA3 used in this work was 1 nM, which is equivalent to 2.5 ng/mL
(considering the molecular weight of about 2.5 kD for a 78 bp fragment of lncRNA-PCA3
transcript). Our previous study based on the same strategy of electrochemical detection of
PCA3 using a redox-labeled aptamer [26] demonstrated a wide detection range of PCA3
from 1 µg/mL down to 0.1 ng/mL. The sensitivity of the proposed electrochemical ap-
tasensor is comparable to the values reported in [11–13] and is thought to be sufficient for
the detection of the PCA3 prostate cancer biomarker in urine.
The concentration of immobilized aptamers must be optimized to achieve the highest
sensitivity. Optical TIRE measurements that show higher sensitivity than CV can distin-
guish between the specific and non-specific binding of PCA3 and can confirm the model of
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aptamer/PCA3 interaction. The XPS measurements provide evidence of strong covalent
binding of aptamers to gold via thiol groups, as well as the interaction between PCA3 and
the aptamer. This study provided us with a better understanding of processes associated
with the aptamer/PCA3 interaction, which is a significant step toward the development of
a simple, cost-effective, and reliable methodology for the early diagnosis of prostate cancer.
Further work should be directed toward optimizing the concentration of immobilized
aptamers to achieve the highest sensitivity of PCA3 detection. Future work will focus on
the use of methods such as DPV, impedance spectroscopy (IS), and TIRE, which appear to
be more sensitive than CV. Additionally, the detection of both PCA3 and PSA in a complex
media of urine is required for further development of quantitative PCa diagnostic tools.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms222312701/s1.
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